Peripheral Arterial Occlusive Disease – Allogeneic
We are recruiting patients with peripheral arterial occlusive disease (PAOD) for a multicentric, randomized, placebo-controlled, double-blind phase I/IIa clinical trial.
The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients with PAOD. Primary endpoints are the percentage of wound size reduction and the occurrence of adverse events.
For this trial 76 patients will be recruited at 9 sites in Germany and Austria.
For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.
Background information about the use of ABCB5+ MSCs in PAOD can be found HERE.